Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL (2016) Pembrolizumab (Keytruda). Hum Vaccin Immunother 12(11):2777–2789. https://doi.org/10.1080/21645515.2016.1199310
Article PubMed PubMed Central Google Scholar
Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B et al (2017) Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 18(5):623–630. https://doi.org/10.1016/S1470-2045(17)30169-9
Article CAS PubMed Google Scholar
Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, Juco J et al (2017) Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 18(2):212–220. https://doi.org/10.1016/S1470-2045(17)30007-4
Article CAS PubMed Google Scholar
Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA (2018) CHECKPOINT INHIBITOR IMMUNE THERAPY: systemic indications and Ophthalmic Side effects. Retina 38(6):1063–1078. https://doi.org/10.1097/IAE.0000000000002181
Article CAS PubMed Google Scholar
Bloch-Michel E, Nussenblatt RB (1987) International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 103(2):234–235. https://doi.org/10.1016/s0002-9394(14)74235-7
Article CAS PubMed Google Scholar
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908–918. https://doi.org/10.1016/S1470-2045(15)00083-2
Article CAS PubMed PubMed Central Google Scholar
Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R et al (2016) Association of Pembrolizumab with Tumor Response and Survival among patients with Advanced Melanoma. JAMA 315(15):1600–1609. https://doi.org/10.1001/jama.2016.4059
Article CAS PubMed Google Scholar
Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN et al (2019) Sex differences in tolerability to Anti-programmed Cell death protein 1 therapy in patients with metastatic melanoma and Non-small Cell Lung Cancer: are we all Equal? Oncologist 24(11):e1148–e1155. https://doi.org/10.1634/theoncologist.2019-0094
Article CAS PubMed PubMed Central Google Scholar
Sun MM, Kelly SP, Mylavarapu Bs AL, Holland GN, Coleman AL, Yu F et al (2021) Ophthalmic Immune-related adverse events after Anti-CTLA-4 or PD-1 Therapy recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Ophthalmology 128(6):910–919. https://doi.org/10.1016/j.ophtha.2020.11.001
Kim YJ, Lee JS, Lee J, Lee SC, Kim TI, Byeon SH et al (2020) Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. Cancer Immunol Immunother 69(12):2441–2452. https://doi.org/10.1007/s00262-020-02635-3
Article CAS PubMed PubMed Central Google Scholar
Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM (2018) Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol 25(5):e403–e410. https://doi.org/10.3747/co.25.4047
Article CAS PubMed PubMed Central Google Scholar
Diem S, Keller F, Rüesch R, Maillard SA, Speiser DE, Dummer R et al (2016) Pembrolizumab-triggered Uveitis: an additional surrogate marker for responders in Melanoma Immunotherapy? J Immunother 39(9):379–382. https://doi.org/10.1097/CJI.0000000000000143
Article CAS PubMed Google Scholar
Sun MM, Levinson RD, Filipowicz ADO, Anesi S, Kaplan HJ, Wang W et al (2020) Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm 28(2):217–227. https://doi.org/10.1080/09273948.2019.1577978
Article CAS PubMed Google Scholar
Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR (2015) A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 26(9):1824–1829. https://doi.org/10.1093/annonc/mdv182
Article CAS PubMed Google Scholar
Men M, Tsui E (2022) Delayed onset anterior uveitis and macular edema after cessation of pembrolizumab. Am J Ophthalmol Case Rep 27:101631. https://doi.org/10.1016/j.ajoc.2022.101631
Article PubMed PubMed Central Google Scholar
Couey MA, Bell RB, Patel AA, Romba MC, Crittenden MR, Curti BD et al (2019) Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 7(1):165. https://doi.org/10.1186/s40425-019-0645-6
Article PubMed PubMed Central Google Scholar
Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T et al (2018) Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3(19):e59125. https://doi.org/10.1172/jci.insight.59125
Article PubMed PubMed Central Google Scholar
Mazharuddin AA, Whyte AT, Gombos DS, Patel N, Razmandi A, Chaudhry AL et al (2022) Highlights on ocular toxicity of Immune Checkpoint inhibitors at a US Tertiary Cancer Center. J Immunother Precis Oncol 5(4):98–104. https://doi.org/10.36401/JIPO-22-14
Article PubMed PubMed Central Google Scholar
Zhou L, Wei X (2021) Ocular Immune-related adverse events Associated with Immune checkpoint inhibitors in Lung Cancer. Front Immunol 12:701951. https://doi.org/10.3389/fimmu.2021.701951
Article CAS PubMed PubMed Central Google Scholar
Chaudot F, Sève P, Rousseau A, Maria ATJ, Fournie P, Lozach P et al (2022) Ocular inflammation Induced by Immune Checkpoint inhibitors. J Clin Med 11(17):4993. https://doi.org/10.3390/jcm11174993
Article CAS PubMed PubMed Central Google Scholar
Dow ER, Yung M, Tsui E (2021) Immune Checkpoint inhibitor-associated Uveitis: review of treatments and outcomes. Ocul Immunol Inflamm 29(1):203–211. https://doi.org/10.1080/09273948.2020.1781902
Article CAS PubMed Google Scholar
Silpa-Archa S, Silpa-Archa N, Preble JM, Foster CS (2016) Vogt-Koyanagi-Harada syndrome: perspectives for immunogenetics, multimodal imaging, and therapeutic options. Autoimmun Rev 15(8):809–819. https://doi.org/10.1016/j.autrev.2016.04.001
Article CAS PubMed Google Scholar
Kuiper J, Rothova A, de Boer J, Radstake T (2015) The immunopathogenesis of birdshot chorioretinopathy; a bird of many feathers. Prog Retin Eye Res 44:99–110. https://doi.org/10.1016/j.preteyeres.2014.11.003
Article CAS PubMed Google Scholar
Yoshida M, Kunikata H, Nakazawa T (2020) Intraocular concentrations of cytokines and chemokines in a unique case of Nivolumab-Induced Uveitis. Ocul Immunol Inflamm 28(6):850–853. https://doi.org/10.1080/09273948.2019.1582785
Article CAS PubMed Google Scholar
Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO et al (2011) CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 22(3):121–130. https://doi.org/10.1016/j.cytogfr.2011.06.001
留言 (0)